Emerging ONC201 Drug Set to Transform Glioblastoma Multiforme Treatment Landscape: Drug Insights and Market Forecasts to 2032
January 29, 2024 12:18 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "ONC201 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This comprehensive report...
Otenaproxesul for Osteoarthritis: A Novel NSAID that Releases Hydrogen Sulfide - Emerging Drug Insight and Market Forecasts, 2019-2023 and 2023-2032
January 24, 2024 09:14 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Otenaproxesul Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
ITI-1000 (pp65 DC vaccine) for Glioblastoma Multiforme (GBM): Emerging Drug Insights and Market Forecasts, 2019-2023 and 2023-2032 - Focus on US, Germany, France, Italy, Spain, UK, and Japan
January 24, 2024 09:09 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "ITI-1000 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
RTX-GRT7039 (Resiniferatoxin) Emerging Drug Insights and Market Forecasts, 2019-2023 and 2023-2032: An Investigational Medicine for the Intra-Articular Treatment of Pain Associated with Knee OA
January 24, 2024 08:01 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "RTX-GRT7039 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
3 Day Online Course: Pharmacovigilance for Drug Safety, Regulatory Affairs and PV Auditors - Broadening your Knowledge Training Course (January 31, 2024 February 2, 2024)
October 02, 2023 07:13 ET
|
Research and Markets
Dublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The "Pharmacovigilance for Drug Safety, Regulatory Affairs and PV Auditors - Broadening your Knowledge Training Course" conference has been added to ...
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
September 26, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
BIMZELX (bimekizumab): The 1st Humanized Monoclonal IgG1 Antibody that Potently and Selectively Neutralizes Both IL-17A and IL-17F - Emerging Drug Insights and Market Forecasts 2019-2023 & 2032
March 31, 2023 07:33 ET
|
Research and Markets
Dublin, March 31, 2023 (GLOBE NEWSWIRE) -- The "Bimekizumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering."Bimekizumab Emerging Drug...
Two Weeks Until Pharmacovigilance for Drug Safety, Regulatory Affairs and PV Auditors - Broadening your Knowledge Training Course (February 22-24, 2023)
February 06, 2023 05:48 ET
|
Research and Markets
Dublin, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The "Pharmacovigilance for Drug Safety, Regulatory Affairs and PV Auditors - Broadening your Knowledge Training Course" conference has been added to ...
3 Day Pharmacovigilance for Drug Safety, Regulatory Affairs and PV Auditors Course (May 30, 2023 - June 1, 2023)
February 01, 2023 14:38 ET
|
Research and Markets
Dublin, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The "Pharmacovigilance for Drug Safety, Regulatory Affairs and PV Auditors - Broadening your Knowledge Training Course" conference has been added to ...
Participants needed for brain injury research studies at Kessler Foundation
October 19, 2016 11:04 ET
|
Kessler Foundation
EAST HANOVER, N.J., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Kessler Foundation is recruiting study participants for multiple research programs aimed at improving cognition, mobility, and long-term outcomes...